Life science instruments & clinical diagnostics. AGI Score 5/10. P/TB ~0.97. $10.6B assets, minimal debt, $7.5B equity. Very cheap to book | Analysis date: 2026-03-13
AGI Score 5/10. Trading near book value with massive excess assets. Bio-Rad has $10.6B in total assets, $7.5B in stockholders equity, minimal debt, and $532M annual OCF on a $7.2B market cap. The company previously held a massive Sartorius AG stake worth billions. The B shares trade at a slight premium to A shares but both classes near book value. At P/TB ~0.97x for a profitable life science company with strong IP, this looks like hidden value.
Bio-Rad manufactures instruments, reagents, and consumables for life science research and clinical diagnostics. Two segments:
| Item | Amount | Notes |
|---|---|---|
| Total Assets | $10.58B | |
| Cash & Investments | ~$2.5B | Substantial cash pile |
| Goodwill | $580M | Only 8% of equity |
| Other Intangibles | $174M | Small |
| Total Liabilities | ~$3.1B | |
| Stockholders Equity | $7.45B | |
| Tangible Book Value | $6.70B | Equity minus goodwill/intangibles |
| Book Value / Share | $276.16 | vs $268.55 market price |
$7.45B equity with only $580M goodwill (8%) and $174M intangibles. Tangible book is $6.70B. Minimal debt. The equity is real — backed by cash, investments, PP&E, and IP. At 0.97x book, you're essentially buying the business at cost.
Note: Bio-Rad previously held a large stake in Sartorius AG (German lab equipment company). This stake was worth several billion and may have been partially sold, explaining the large equity base.
| Item | Latest | Notes |
|---|---|---|
| Revenue | $2.58B | |
| Gross Profit | ~$1.4B | ~54% gross margin |
| Net Income | $760M | Includes investment gains |
| EPS | $27.86 | 9.4x P/E |
| Operating Cash Flow | $532M | 7.4% OCF yield |
| FCF | $257M | 3.6% FCF yield |
Bio-Rad's products enable biological research that AGI will accelerate — AI-driven drug discovery and precision medicine expand demand. However, innovation risk is significant: AGI could enable in silico pathology and computational biology that replaces wet lab work. The installed base of instruments generates recurring reagent revenue, providing stickiness. Physical consumables and regulatory certifications create switching costs.
Current market cap: $7.2B. 10x = $72B. Danaher (life science conglomerate) is ~$160B. $72B is aggressive but not impossible if Bio-Rad gets acquired or dramatically grows.
10x entry price: $72B / 10 / ~27M total shares = ~$267/share. That's roughly today's price. So if you believe Bio-Rad can reach $72B, buying today gives you 10x. But $72B requires ~$7B revenue at 10x P/S, or $4B net income at 18x P/E. Both require major growth from $2.6B revenue.
More likely 2-3x: If the market re-rates to 1.5-2x book ($414-552/share) as it recognizes the clean balance sheet and cash generation, that's a solid double.
Acquisition target: Bio-Rad's dual-class share structure (A and B shares) means the founding Schwartz family controls the company. Acquisition requires their consent. If they agree to sell, a strategic buyer (Danaher, Thermo Fisher, Roche) could pay 2-3x current price.
Floor price: $180-200/share (0.65-0.75x book). With $6.7B tangible equity, minimal debt, and $532M OCF, it's hard to see permanent impairment below 0.65x book.
Bio-Rad at 0.97x book with a clean balance sheet, 54% gross margins, and $532M OCF is objectively cheap. The tangible assets are real (cash, investments, PP&E), goodwill is small, and the business generates cash. At 9.4x P/E, the market is pricing in very low growth.
The Schwartz family control is a double-edged sword: it prevents hostile takeovers but also limits capital allocation flexibility and shareholder activism.
Floor price: $180-200. Entry zone: below $220 (0.8x book). Acquisition scenario could unlock 2-3x upside.
Bio-Rad's market cap is $7.2B. Its Sartorius stake alone is worth ~$4.7B at current market prices ($5.7B as stated in the 10-K at year-end). Its operating business generates $374M in FCF. It has $2.5B in cash and investments beyond Sartorius, against $1.2B in debt. The sum-of-parts says $11-14B. The market says $7.2B. That's a 37-50% discount. Why?
Bio-Rad has a dual-class share structure where Class A gets one-tenth of a vote and Class B gets one full vote. For director elections, the classes vote separately: Class A elects 25% of the board, Class B elects 75%. The Schwartz family (founders) hold a majority of the voting stock. This means:
The market treats family-controlled companies with heavy governance discounts. Bio-Rad is an extreme case because (a) the voting asymmetry is 10:1, (b) the family controls 75% of board elections, and (c) there is no realistic path to unlocking value without family cooperation.
| Year | Revenue | Op Income | Op Margin | OCF |
|---|---|---|---|---|
| FY2022 | $2,802M | $483M | 17.2% | $194M |
| FY2023 | $2,671M | $338M | 12.7% | $375M |
| FY2024 | $2,567M | $269M | 10.5% | $455M |
| FY2025 | $2,583M | $47M | 1.8% | $532M |
Revenue has dropped 8% from $2.8B to $2.58B over three years. Operating income has cratered from $483M to $47M (FY2025 includes a $173M intangible impairment charge). Even adjusting for impairment, operating income is ~$220M, down 54% from 2022. The life science market is in a cyclical downturn: biotech funding is constrained, government research spending is flat, and China is weak. This is not a growth story.
Bio-Rad owns 12.99M ordinary voting shares (38% of outstanding) and 9.59M preference shares (28%) of Sartorius AG. The stake is marked to market through net income, creating extreme volatility:
| Year | Sartorius Gain/(Loss) | Reported Net Income | Reality |
|---|---|---|---|
| FY2020 | +$4,496M | $4,773M | Massive gain inflated earnings |
| FY2021 | +$4,926M | $5,098M | More gains |
| FY2022 | -$5,194M | -$4,893M | Sartorius crash wiped out years of gains |
| FY2023 | -$1,252M | $350M | Mixed |
| FY2024 | -$2,657M | -$1,844M | Another Sartorius drop |
| FY2025 | +$900M | $760M | Recovery, but op income only $47M |
The P/E of 9.4x is meaningless because $760M net income includes $900M in unrealized Sartorius gains. Core operating earnings are approximately $0 after impairments, or ~$170M adjusted. On that basis, the P/E is more like 42x operating earnings. The market sees through the Sartorius noise and prices the operating business appropriately (or slightly cheaply).
Bio-Rad owns 38% of Sartorius ordinary shares. This is not a position you can sell on a Tuesday. Any significant sale would:
The market appropriately discounts the Sartorius stake for illiquidity, tax leakage, and execution risk. A 20-30% haircut on the Sartorius stake value is rational, not irrational.
There are only 5.07M Class B shares outstanding vs 21.9M Class A shares. The B shares have MORE voting power (1 vote vs 0.1 vote for A shares), yet trade at only a slight premium (~$268 vs ~$263 for A shares, a 2% premium). In most dual-class structures, the super-voting shares trade at a significant premium. Bio-Rad B shares don't because:
Partially yes, partially no.
The cheapness is structural, not temporary. It will persist until: (a) the Schwartz family sells the company, (b) they sell down the Sartorius stake and return capital, or (c) the operating business returns to growth. None of these have a clear catalyst.
| Period | Shares Bought | Avg Price | Spent |
|---|---|---|---|
| May 2023 | 549,863 | $377.20 | $207M |
| Sep 2023 | 58,478 | $364.61 | $21M |
| Nov 2023 | 659,416 | $303.30 | $200M |
| Mar-Aug 2024 | 690,857 | $291 | $201M |
| Mar-Aug 2025 | 1,205,381 | $245 | $296M |
| Total (since May 2023) | 4,323,770 | $265 | $715M |
$1B authorized, $715M spent, $285M remaining. They are buying back stock aggressively at prices below book value. That is exactly what you want management to do. In July 2024, the board added another $500M to the buyback program. Shares outstanding have dropped from ~30.2M (2021) to ~27.3M (2025), a 10% reduction.
Bio-Rad does not disclose granular product-line revenue ("it is impractical to do so based primarily on the numerous products"). However, we know the two segments and can identify the major product categories from 10-K disclosures and industry knowledge.
Develops, manufactures, and markets instruments, systems, reagents, and consumables for biological research and biopharmaceutical manufacturing. TAM: ~$19B.
| Product Category | Description | AGI Impact |
|---|---|---|
| Electrophoresis & Blotting | Gel electrophoresis systems, western blotting, protein transfer systems. Bio-Rad is a market leader. Used to separate and identify proteins/DNA. | Neutral to Mildly Negative |
| Real-Time PCR (qPCR) | CFX series thermal cyclers and detection systems for gene expression analysis, SNP genotyping, pathogen detection. Flagship product line. | Positive |
| Droplet Digital PCR (ddPCR) | QX series systems for absolute quantification of nucleic acids. Used in liquid biopsy, rare mutation detection, gene editing validation. Premium technology. | Strongly Positive |
| Cell Biology (Cell Counting, Flow Cytometry) | ZE5 cell analyzers, TC20 cell counters, S3e cell sorters. Cell characterization and sorting. | Neutral |
| Chromatography & Protein Purification | Process chromatography resins (e.g., CHT ceramic hydroxyapatite) for biopharmaceutical manufacturing (antibody purification). | Positive |
| Food Safety Testing | Pathogen detection systems for food production facilities. | Neutral |
| Antibodies & Reagents | Extensive catalog of primary/secondary antibodies, assay kits, and specialty chemicals. High-margin consumables. | Neutral to Negative |
Diagnostic test systems, informatics, specialized quality controls. TAM: ~$16B. Revenue is largely recurring (installed base + consumables).
| Product Category | Description | AGI Impact |
|---|---|---|
| Quality Controls | Third-party quality control products that clinical labs use to verify their test systems are working correctly. Bio-Rad is the global leader. Used across all lab disciplines. Required by CLIA regulations. | Positive (Regulatory Moat) |
| Blood Typing / Immunohematology | IH-1000 and IH-500 automated blood typing systems for transfusion medicine. Reagents for blood group, antibody screening. | Neutral (Regulatory Moat) |
| Diabetes Monitoring (HbA1c) | D-100 and D-10 HPLC systems for hemoglobin A1c testing. Diabetes management. Under reimbursement pressure in China. | Negative |
| Autoimmune Testing | BioPlex 2200 multiplex immunoassay system for autoimmune disease markers (ANA, anti-dsDNA, etc.). | Mildly Negative |
| Clinical Microbiology | Identification systems for bacterial/fungal identification. | Negative |
| Informatics / Lab Software | Unity Real Time quality management software, lab data management solutions. | Positive |
From the gold analysis framework: physical things that serve a function AGI cannot replicate digitally retain value. Bio-Rad's products are physical instruments and chemical reagents that interact with biological samples. You cannot digitally simulate a Western blot or computationally purify an antibody. The atoms must move.
However, unlike gold, Bio-Rad's products are tools, not stores of value. Tools can be replaced by better tools. If AGI enables a fundamentally different approach to biological research (fully computational biology, in silico drug trials), the tools become obsolete. The key question is: how much of biology can be done computationally vs. physically?
Current answer: very little. Biology is too complex for pure computation. Wet lab validation remains essential. But this could change with AGI + advanced simulation. Timeline: 10-20 years, not 3-5 years. Bio-Rad's products are safe for our investment horizon.
The score of 5 is appropriate. The positive forces (AI-driven drug discovery boosting instrument demand, regulatory moats on QC) roughly balance the negative forces (computational biology reducing some wet lab work, HbA1c decline). The net effect is neutral over 5 years, mildly positive or mildly negative over 10 years depending on AGI capability in biological simulation.
Revenue-weighted impact: ~35% of revenue benefits from AGI (QC, ddPCR, process chromatography), ~25% is harmed (HbA1c, microbiology, electrophoresis), ~40% is neutral (blood typing, food safety, cell biology). Net: slightly positive.
| Component | Shares | Price (EUR) | Value (USD) |
|---|---|---|---|
| Sartorius Ordinary (voting) | 12,987,900 | 209.70 | $2.97B |
| Sartorius Preference (non-voting) | 9,588,908 | 165.00 | $1.72B |
| Total Sartorius (market value) | $4.69B | ||
| 10-K stated value (12/31/2025) | $5.67B | ||
| After 25% illiquidity/tax haircut | $3.52B |
Note: Using EUR/USD = 1.09. The 10-K stated $5.67B as of 12/31/2025; current market value is lower at ~$4.69B (Sartorius has declined in 2026). A 25% haircut for illiquidity and deferred tax is conservative but realistic for a 38% block position.
| Metric | Value | Notes |
|---|---|---|
| Revenue | $2,583M | Flat/declining |
| Gross Profit | $1,340M | 51.9% margin |
| Adjusted Operating Income | $220M | Excluding $173M impairment |
| Operating Cash Flow | $532M | Improving despite revenue weakness |
| CapEx | $158M | |
| Free Cash Flow | $374M | 14.5% FCF margin |
| Valuation Method | Multiple | Op Business Value |
|---|---|---|
| FCF multiple (conservative) | 15x | $5.6B |
| FCF multiple (moderate) | 20x | $7.5B |
| Revenue multiple (peers: Danaher, TMO) | 2-3x | $5.2-7.7B |
| Adj. Operating Income (15x) | 15x | $3.3B |
| Component | Conservative | Moderate | Aggressive |
|---|---|---|---|
| Sartorius stake | $3.5B (25% haircut) | $4.7B (market) | $5.7B (10-K) |
| Operating business | $3.3B (15x adj OI) | $5.6B (15x FCF) | $7.5B (20x FCF) |
| Net cash (ex-Sartorius, ex-debt) | $1.3B | $1.3B | $1.3B |
| Total SOTP | $8.1B | $11.6B | $14.5B |
| Per share (~27M shares) | $300 | $429 | $537 |
| Discount from market ($268) | 11% | 37% | 50% |
Even the conservative case (25% haircut on Sartorius, 15x adjusted operating income) gives $300/share, 12% above current price. The moderate case (market-value Sartorius, 15x FCF) gives $429/share, 60% upside. The market is pricing in the conservative case or worse.
The critical insight: the discount is almost entirely a governance discount. The assets are real, the cash flows are real, but shareholders have no mechanism to force the Schwartz family to unlock value. You are betting on the family's eventual decision to sell, spin off Sartorius, or return capital -- or on the operating business recovering to make the discount irrelevant.
| Metric | Value |
|---|---|
| Consensus Rating | Buy (Strong Buy from StockAnalysis) |
| Number of Analysts | 4-5 |
| Average Price Target | $358 |
| Low Target | $280 |
| High Target | $375 |
| Forward P/E | 25.7x |
| Short Interest (% float) | 4.9% |
| Insider Ownership | 16.3% |
| Institutional Ownership | 92.4% |
Analysts see 33% upside to their average target of $358. The forward P/E of 25.7x (vs trailing 9.4x) implies analysts expect FY2025's $760M net income to normalize much lower (to ~$280M, or ~$10.50/share). This is consistent with our analysis: strip out Sartorius gains and operating earnings are ~$170-220M.
| Feature | Class A (BIO) | Class B (BIO-B) |
|---|---|---|
| Price | ~$263 | ~$269 |
| Shares Outstanding | 21.9M (81%) | 5.07M (19%) |
| Voting Power (general) | 0.1 vote/share | 1.0 vote/share (10x A) |
| Board Election | Elects 25% of board | Elects 75% of board |
| Dividend Rights | May get dividends without B getting any | Cannot get dividends unless A gets equal or more |
| Conversion | Not convertible | Convertible to A shares 1:1 |
| EPS Participation | Equal | Equal |
| Non-Affiliate Float | ~$4.4B | ~$24M (almost nothing) |
| Liquidity | Good | Very thin |
Class A (BIO) is clearly better for outside investors. The B shares trade at a slight premium ($6/share, ~2%) for 10x voting power that is meaningless because the Schwartz family already controls the company. The B shares have almost no float ($24M held by non-affiliates) and abysmal liquidity. The A shares have $4.4B in public float and decent volume.
The ONLY reason to buy B shares: if you believe the Schwartz family will eventually take the company private and must offer a premium for B shares. Otherwise, A shares are the rational choice.
Bio-Rad has multiple Schedule 13D filings, primarily from Schwartz family members and related entities (not outside activists). The most recent 13D/A amendments were filed in October 2025, likely updating the family's ownership positions. There are no known outside activist campaigns targeting Bio-Rad -- the dual-class structure makes activism futile.
The 13G filers include standard institutional holders (Vanguard, BlackRock, etc.) who are passive investors, not activists.
Bio-Rad is genuinely cheap on a sum-of-parts basis (37-50% discount). The assets are real: $4.7B Sartorius stake, $2.5B cash/investments, $540M PP&E, an operating business generating $374M FCF. Against $1.2B debt. Total tangible value: $8-14B on a $7.2B market cap.
But the discount is structural, not catalytic. There is no mechanism for outside shareholders to force value realization. The Schwartz family controls the company absolutely via the dual-class structure. There are no activists, no hostile bids, no board fights. The family has run Bio-Rad as a private fiefdom for 70+ years and shows no signs of changing.
The operating business is mediocre: flat/declining revenue ($2.8B to $2.58B over 3 years), collapsing operating margins (17% to 2%), and a management team focused on R&D and restructuring rather than growth. AGI is roughly neutral (score 5/10). This is not a growth story.
What makes it interesting despite all this:
Floor price: $180-200 (unchanged). Entry zone: below $230. Preferred share class: Class A (BIO), not Class B (BIO-B).
Catalyst watch: Schwartz family succession event, Sartorius stake monetization, acquisition by Danaher/TMO/Roche, or life science market recovery driving revenue back above $2.8B.
Data sources: SEC EDGAR XBRL (CIK 0000012208), yfinance, 10-K filing (FY2025, filed 2026-02-13), StockAnalysis.com, AGI scoring model. Analysis date: 2026-03-14.